Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction Between Amikacin and Murepavadin in Healthy Subjects
NCT02897869Phase 1Completed
- Sponsor
- Polyphor
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of murepavadin in Pseudomonas aeruginosa infection (2 arms), sponsored by Polyphor. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Apr 2016; status: completed.
02
Drugs
murepavadin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02897869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897869.